¹Ø×¢ÃÀ¸ß÷Medicilon¹«Öںţ¬£¬£¬£¬ÔÚÖ÷ҳ̸Ìì¿ò»Ø¸´¡°ÊµÑ鱨¸æ¡±£¬£¬£¬£¬¼´¿ÉÉó²é¡°Ä³Ä¿µÄÂѰ×PROTAC-POIÌåÍâɸѡ¡±µÄÏêϸʵÑ鱨¸æ£¡

PROTAC¼¼Êõ×÷ÓûúÖÆÆæÒì

1.PROTAC·Ö×Óͨ¹ýÆäÒ»¶ËµÄ°ÐÂѰ×ÅäÌ壨POI Ligand£©ÌØÒìÐÔʶ±ð²¢Á¬Ïµ°ÐÂѰף¬£¬£¬£¬Í¨¹ýÆäÁíÒ»¶ËµÄE3·ºËØÅþÁ¬Ã¸ÅäÌ壨E3 Ligase Ligand£©ÌØÒìÐÔʶ±ð²¢Á¬ÏµE3 Ligase£»£»£»
2.ÐγÉP O I - P R O T A C - E 3ligaseÈýÔª¸´ºÏÌ壻£»£»
3.ÔÚ´ËÈýÔª¸´ºÏÌåÖУ¬£¬£¬£¬°ÐÂѰ×POI±»E3 ligase·ºËØ»¯ÐÞÊΣ¬£¬£¬£¬·ºËØ»¯ÐÞÊÎÁ˵ÄPOIËæºó±»ÂѰ×øÌåʶ±ð²¢½µ½â£¬£¬£¬£¬ÓÉ´ËÒÖÖÆ°ÐÂѰ׵Ĺ¦Ð§
PROTAC¼¼ÊõÔÚÒ©ÎïÑз¢·½ÃæµÄÓÅÊÆ
¸Ä±ä°ÐµãµÄ¡°²»¿É³ÉÒ©ÐÔ¡±£¨undruggable£©
PROTACµÄ×÷Ó÷Ö×Ó»úÖÆÊÇͨ¹ý·ºËØ-ÂѰ×øϵһÇнµ½â°ÐÂѰף¬£¬£¬£¬²¢·Çͨ¹ý¾ºÕùÁ¬ÏµÒԹرհÐÂѰ׹¦Ð§Çø¶øÊ©Õ¹ÂѰ׹¦Ð§ÒÖÖÆ×÷Ó㬣¬£¬£¬Òò´ËPROTAC¶Ô°ÐÂѰ×ʶ±ðÁ¬ÏµÇø·×Æç¶¨·ÇµÃÊÇ»îÐÔÇø£¬£¬£¬£¬½áÐÁ¦Ò²·×Æç¶¨±ØÐèÊǸßÇ׺ÍÁ¦£»£»£»ÕâʹµÃһЩȱ·¦¸ßÇ׺ÍÁ¦Ð¡·Ö×ÓÁ¬ÏµµÄ¡°²»¿É³ÉÒ©ÐÔ¡±°ÐÂѰ×Äð³É¡°¿É³ÉÒ©ÐÔ¡±;
¸ßЧÐÔ
¹Å°åС·Ö×ÓÒÖÖÆ¼Áͨ¹ý¾ºÕùÁ¬Ïµ°ÐÂѰ׻îÐÔ¹¦Ð§Óò¶øÒÖÖÆ°ÐÂѰ׹¦Ð§£¬£¬£¬£¬ËùÐèС·Ö×ÓµÄÁ¿ÍùÍù½Ï´ó£»£»£»¶øPROTACͨ¹ý·ºËØ-ÂѰ×øϵһÇнµ½â°ÐÂѰ×ÒÔɨ³ý°ÐÂѰ׹¦Ð§£¬£¬£¬£¬¹Ê¾ßÓпÉÑ»·Ê¹ÓÃÐÔ¡¢ÓÃÁ¿µÍºÍ¸ßЧÐÔµÄÌØµã¡£¡£¡£¡£¡£
ÎÞÃâÒßÔÐÔ
Ó뿹ÌåÒ©ÎïÏà±È£¬£¬£¬£¬PROTAC²»»áÒý·¢¿¹Ò©¿¹Ì屬·¢¡£¡£¡£¡£¡£
×ÛÉÏ£¬£¬£¬£¬PROTACÒѳÉΪҩÎïÑз¢ÁìÓòµÄÐÂÐËÀûÆ÷£¬£¬£¬£¬ÔÚº£ÄÚÍⱸÊÜ¿ÆÑе¥Î»¼°Ò©ÆóËù×·Åõ¡£¡£¡£¡£¡£
ÃÀ¸ß÷PROTAC¼¼ÊõЧÀͽéÉÜ
°Ð±êÂѰ×PROTAC-POIµÄÉè¼ÆºÏ³É
ÃÀ¸ß÷»ã×ÜÁËÄ¿½ñÊ¢ÐеÄÈÈÃÅPOIÅäÌ壬£¬£¬£¬²î±ð×éÖ¯ÀàÐ͵ÄE3ligaseÅäÌ壬£¬£¬£¬²¢ÇÒ½¨ÉèÁ˺¬Êý°ÙÖÖÅþÁ¬·Ö×ÓµÄlinker¿â¡£¡£¡£¡£¡£
±ðµÄ£¬£¬£¬£¬ÃÀ¸ß÷³ÉÊìµÄÅÌËã»ú¸¨ÖúÒ©ÎïÉè¼Æ¼¼Êõƽ̨£¬£¬£¬£¬´ó´óÌá¸ßPROTAC-POIµÄÉè¼ÆºÏ³ÉÖÊÁ¿¡£¡£¡£¡£¡£
PROTAC-POIµÄÌåÍâɸѡ
HEK 293TÎÈתÖêϸ°û£¨POI-EGFP£©¸ßͨÁ¿É¸Ñ¡
ʹÓûùÒòÇÃÈë¼¼Êõ¹¹½¨µÄ¡°ÄÚÔ´ÂѰ×-EGFP¡±293TÎÈתÖêϸ°û£¬£¬£¬£¬¶ÔPROTAC·Ö×Ó¾ÙÐиßͨÁ¿É¸Ñ¡£¬£¬£¬£¬ÅÌËãDC50¡£¡£¡£¡£¡£

Percentage reduction in POI-EGFP fusion protein level
Western Blot£¨WB£©
ͨ¹ýWBʵÑé¼ì²â³õɸµ½µÄPROTAC·Ö×Ӷ԰бêÂѰ׵Ľµ½âÄÜÁ¦£¬£¬£¬£¬ÆÊÎöDC50Öµ¡£¡£¡£¡£¡£

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI
ϸ°û¶¾ÐÔʵÑ飨CCK-8»òCTG·¨£©
¼ì²âÉÏÊöɸѡµ½PROTC-POI¶Ô°©Ï¸°ûÔöÖ³ÒÖÖÆÄÜÁ¦£¬£¬£¬£¬ÆÊÎöIC50Öµ¡£¡£¡£¡£¡£
»úÖÆ¼ì²â
a. ¼ì²âPROTACÊÇ·ñͨ¹ýE3 CRBN¶Ô°ÐÂѰ׾ÙÐнµ½â¡£¡£¡£¡£¡£

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI
b. ÌØÒìÐÔ¼ì²â£ºÍ¨¹ýʹÓÃLC-MS/MS¾ÙÐÐÂѰ××éѧÆÊÎö£¬£¬£¬£¬È·¶¨PROTAC½µ½âÂѰ׵ÄÌØÒìÐÔ£»£»£»Ê¹ÓÃKINOMEscanÆÊÎöPROTAC¶Ô¼¤Ã¸Á¬ÏµµÄÌØÒìÐÔ¡£¡£¡£¡£¡£

Proteasome system mediates PROTAC-POI-induced POI Degradation
Ö×Áöϸ°ûµÄÔöÖ³ÒÖÖÆÐ§Ó¦
ʹÓÃCCK-8»òCTG·¨£¬£¬£¬£¬¼ì²âPROTAC¶ÔÖ×Áöϸ°ûµÄÔöÖ³ÒÖÖÆÐ§¹û¡£¡£¡£¡£¡£

Proliferation inhibition effects of POI in the indicated cell lines at 120 h after treatment
PROTAC-POIµÄ¶¯ÎïÌåÄÚҩЧɸѡ
CDXСÊóÖ×ÁöÄ£×Ó
½«ÏìÓ¦°©ÖÖϸ°ûÏµÒÆÖ²µ½ÂãÊó»òNSGСÊóÌåÄÚ£¬£¬£¬£¬½¨ÉèÆ¤ÏÂÁö»òÔλÁöÄ£×Ó£¬£¬£¬£¬Í¨¹ý¿Ú·þ¡¢¹àθ»ò¾²Âö¸øÒ©£¬£¬£¬£¬¼ì²âÌåÍâɸµ½µÄPROTAC-POI¶ÔÊóÌåÄÚÖ×ÁöÉú³¤µÄÒÖÖÆÐ§¹û¡£¡£¡£¡£¡£

PDXСÊóÖ×ÁöÄ£×Ó
½«Ö×Áö×éÖ¯ÒÔ×éÖ¯¿éµÄÐÎÊ½ÒÆÖ²µ½NSGСÊóÌåÄÚ£¬£¬£¬£¬ÕâЩÖ×Áö×éÖ¯ÔÚNSGСÊóÌåÄÚ¼á³ÖÁËÔʼÖ×ÁöµÄÉúÎïÑ§ÌØÕ÷£¬£¬£¬£¬ÓëÁÙ´²ÌØÕ÷ÏàËÆ¶È¸ü¸ß¡£¡£¡£¡£¡£Ê¹ÓÃPDXСÊóÄ£×Ó¼ì²âPROTAC-POI¶ÔÌåÄÚÖ×ÁöÉú³¤µÄÒÖÖÆÐ§¹û¡£¡£¡£¡£¡£

PK/PDÑо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û
¶Ô¶¯ÎïÌåÄÚҩЧ¼ì²âɸѡ»ñµÃµÄÀíÏëµÄPROTAC-POI¾ÙÐÐPK/PDÑо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û£¬£¬£¬£¬²¢»ã×ÜʵÑéЧ¹ûºÍÖÊÁϾÙÐÐINDÉ걨£¬£¬£¬£¬ÒÔÖúÁ¦¿Í»§¼ÓËÙPROTAC-POIÒ©ÎïµÄÑз¢Àú³Ì¡£¡£¡£¡£¡£
ɨÃèÏ·½¶þάÂ룬£¬£¬£¬¹Ø×¢ÃÀ¸ß÷Medicilon¹«Öںţ¬£¬£¬£¬ÔÚÖ÷ҳ̸Ìì¿ò»Ø¸´¡°ÊµÑ鱨¸æ¡±£¬£¬£¬£¬¼´¿ÉÉó²é¡°Ä³Ä¿µÄÂѰ×PROTAC-POIÌåÍâɸѡ¡±µÄÏêϸʵÑ鱨¸æ£¡

ÁªÏµÃÀ¸ß÷
Email: marketing@medicilon.com.cn
µç»°: +86 (21) 5859-1500£¨×Ü»ú£©